NEW YORK (GenomeWeb News) — “Policy forces” inside the US government are preventing genomic technologies from helping physicians make off-label prescribing decisions, according to a prominent US Food and Drug Administration official.
 
“Medicine is becoming more personalized as tools like genomics make it possible to tailor treatments on an individual basis,” Scott Gottlieb, deputy commissioner for medical and scientific affairs, said in a speech at Windhover's FDA/CMS Summit in Washington, DC, earlier this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.